Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma

References

1. ↵
   1. Meriggioli MN,
   2. Sanders DB

   (2009) Autoimmune myasthenia gravis:emerging clinical and biological heterogeneity. Lancet Neurol 8, 475–490.
2. ↵
   1. Kairouz S,
   2. Hashash J,
   3. Kabbara W,
   4. McHayleh W,
   5. Tabbara IA

   (2007) Dendritic cell neoplasms:an overview. Am J Hematol 82, 924–928.
3. ↵
   1. Zouvelou V,
   2. Zisimopoulou P,
   3. Psimenou E,
   4. Matsigkou E,
   5. Stamboulis E,
   6. Tzartos SJ

   (2014) AChR-myasthenia gravis switching to double-seropositive several years after the onset. J Neuroimmunol 267, 111–112.
4. ↵
   1. Yang CS,
   2. Yang L,
   3. Li T,
   4. Zhang DQ,
   5. Jin WN,
   6. Li MS,
   7. et al.

   (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81, 710–713.